ARTICLE | Clinical News
Pollinex Quattro Grass: Phase III hold
July 16, 2007 7:00 AM UTC
Allergy Therapeutics plc (LSE:AGY), London, U.K. AllerPharma Inc., Toronto, Ontario Product: Pollinex Quattro Grass Business: Inflammation Molecular target: Not applicable Description: Subcutaneous ...